Congress may let pharma sue states over drug restrictions

What it does

This bill creates a federal statutory right for individuals to obtain FDA-approved medicines and for healthcare providers to prescribe them, and prohibits federal or state laws from restricting access to FDA-approved drugs unless the restriction significantly advances access and has no less restrictive alternative. It grants individuals and providers a private right of action to sue states and government officials who violate these rights, with attorney's fees and costs awarded to prevailing plaintiffs.

Why we flagged it

The bill's core mechanism is not to mandate drug coverage or subsidies, but to create a federal cause of action against state and local health regulations that restrict FDA-approved medicines. It is fundamentally a litigation-enabling statute that reframes drug access as a constitutional-style right enforceable in federal court.

What the text implies

• The 'clear and convincing evidence' standard for defending state/local restrictions is unusually high and may invalidate longstanding public-health regulations (e.g., pharmacy licensing, controlled-substance monitoring, insurance formulary rules) without explicit legislative intent to do so.
• Private right of action with mandatory attorney's fees creates incentive for pharmaceutical companies or patient-advocacy groups funded by pharma to litigate against state health policies, shifting regulatory authority from elected officials and health agencies to federal courts.

The full analysis lists 5 implications of this text.

Who stands to gain

pharmaceutical manufacturers (especially those with FDA-approved drugs facing state-level restrictio; specialty pharmaceutical companies (higher-cost drugs often subject to state cost-control measures); patient-advocacy organizations funded by pharmaceutical companies